(14.) Li C, Sutherland CA, Nightingale CH, Nicolau DP Quantitation of tigecycline, a novel glycylcycline
[corrected] by liquid chromatography.
Tigecycline (TGC) is only commercially available glycylcycline
and was approved in 2005 (8).
Tigecycline is a new glycylcycline
derivative of tetracycline, which is bacteriostatic in nature and effective against both Gram-positive as well as Gram-negative organisms.
One is tigecycline, the first drug in the glycylcycline
class of antibiotics, and the other is ceftaroline fosamil, a broad-spectrum cephalosporin.
Rates of antimicrobial resistance in Latin America (2004-2007) and in vitro activity of the glycylcycline
tigecycline and of other antibiotics.
Another drug, tigecycline (a glycylcycline
), has shown good activity against MRSA strains in vitro (3).
[sup] Tigecycline is a glycylcycline
with a wide spectrum of activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria.
Prevalence and regional variation in meticillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcycline
Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline
However, recent reports of resistance to colistin are emerging.28 Tigecycline, a glycylcycline
, is recommended for resistant skin, soft tissue and intra- abdominal infections and is not a good option for blood stream infections and urinary tract infections.24
However tigecycline, a glycylcycline
antimicrobial, is in use for several years with a mechanism of entering the bacterial cell through energy-dependent pathways or via passive diffusion, and then binding to the subunit 30S of the ribosomes, resulting the inhibition of protein syntesis of the microorganism.
In our study, all the13 strains were found to be colistin sensitive.19Tigecycline is a glycylcycline
derived antibioticwhich is in vitro effective on MDR A.baumannii.Baadani et al20 found tigecycline resistance as 4.7-20.5% in the A.